Kenneth Erland Johnson - Jan 31, 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Senior Vice President, Global Development and Medical Affairs
Signature: /s/ Beth Hecht, as Attorney-in-Fact
Stock symbol: XERS
Transactions as of: Jan 31, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/31/2024, 05:04 PM
Previous filing: Feb 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Award	$0	+175K	+64.37%	$0.00	447K	Jan 31, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2	These shares include 2,077 shares that were purchased on June 30, 2023 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.

Remarks:

Senior Vice President, Global Development and Medical Affairs